Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7%

InflaRx (NASDAQ:IFRX - Get Free Report) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 415,200 shares, a decline of 13.7% from the January 15th total of 481,300 shares. Based on an average trading volume of 305,500 shares, the days-to-cover ratio is presently 1.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of InflaRx in a research report on Thursday, January 16th.

InflaRx Trading Down 2.9 %

Shares of NASDAQ:IFRX traded down $0.06 during trading on Thursday, reaching $1.85. 267,405 shares of the stock were exchanged, compared to its average volume of 375,809. The firm has a market cap of $108.93 million, a PE ratio of -1.71 and a beta of 1.63. The stock has a 50-day moving average price of $2.39 and a 200-day moving average price of $1.92. InflaRx has a 12 month low of $1.17 and a 12 month high of $2.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northern Trust Corp boosted its stake in shares of InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company's stock valued at $1,647,000 after buying an additional 634,045 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of InflaRx in the 4th quarter valued at approximately $55,000. Geode Capital Management LLC increased its stake in InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after acquiring an additional 11,900 shares during the last quarter. Two Sigma Securities LLC bought a new stake in InflaRx during the fourth quarter worth $28,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of InflaRx in the 4th quarter valued at $1,576,000. Institutional investors and hedge funds own 42.39% of the company's stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.